When was Brooklyn ImmunoTherapeutics founded?

Brooklyn ImmunoTherapeutics was founded in 2018 and raised its 1st funding round 4 years after it was founded.

Where is Brooklyn ImmunoTherapeutics located?

Brooklyn ImmunoTherapeutics is headquartered in New York City, United States.

How many employees does Brooklyn ImmunoTherapeutics have?

As of May 31, 2026, the latest employee count at Brooklyn ImmunoTherapeutics is 9.

Is Brooklyn ImmunoTherapeutics a funded company?

Brooklyn ImmunoTherapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Mar 09, 2022.

When was the latest funding round of Brooklyn ImmunoTherapeutics?

Brooklyn ImmunoTherapeutics' latest funding was a $***** Post IPO round on Mar 09, 2022, with participation from 0 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.23B in funding in 2026 to date.

Where does Brooklyn ImmunoTherapeutics rank among its competitors?

Brooklyn ImmunoTherapeutics ranks 1432nd amongst 3301 active competitors, of which 1122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Brooklyn ImmunoTherapeutics?

Brooklyn ImmunoTherapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Brooklyn ImmunoTherapeutics - 2026 Company Profile, Funding & Competitors

Brooklyn ImmunoTherapeutics is a late stage company based in New York City (United States), founded in 2018. It operates as a Developer of cytokine-based therapeutics for treating cancer. Brooklyn ImmunoTherapeutics has raised an undisclosed amount in funding. The company has 3301 active competitors, including 1122 funded and 778 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of cytokine-based therapeutics for treating cancer. The company's lead product candidate IRX-2 is an allogeneic, reproducible, primary, cell-derived biologic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. This, in turn, activates the antibodies to target the tumor and travel to the primary and metastatic sites. This also can be used against head and neck cancer.

Website: brooklynitx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

New York City, United States

Stage

Late Stage

Latest Funding Round

Post IPO, Mar 09, 2022, $*****

Investors

Purchase Capital & 2 more

Ranked

1432^nd among 3301 active competitors

Employee Count

9 as on May 31, 2026

Investment & Acquisitions

Novellus & 1 more

Similar Companies

Jazz Pharmaceuticals & 3000 more

View Brooklyn ImmunoTherapeutics' full profile

Brooklyn ImmunoTherapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Brooklyn ImmunoTherapeutics, Inc. CIN: 31-1103425 , United States, Active	Dec 31, 2017	-	14 (As on Dec 31, 2021)	-

Brooklyn ImmunoTherapeutics has raised funding over 1 round. Brooklyn ImmunoTherapeutics has 3 institutional investors.

Here is the list of recent funding rounds of Brooklyn ImmunoTherapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 09, 2022	9629107	Post IPO	2464249	7314846	2639575	1722156

Access funding benchmarks and valuations. Sign up today!

View details of Brooklyn ImmunoTherapeutics's funding rounds and investors

Brooklyn ImmunoTherapeutics' employee count trend

Brooklyn ImmunoTherapeutics has 9 employees as of May 26. Here is Brooklyn ImmunoTherapeutics's employee count trend over the years:

Employee count trend for Brooklyn ImmunoTherapeutics

Uncover Brooklyn ImmunoTherapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Brooklyn ImmunoTherapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Brooklyn ImmunoTherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1432nd	Brooklyn ImmunoTherapeutics 2018, New York City (United States), Late Stage	Developer of cytokine-based therapeutics for treating cancer	-	Purchase Capital, Prettybrook Partners & 1 others	35/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Brooklyn ImmunoTherapeutics's competitors? Click here to see the top ones

Brooklyn ImmunoTherapeutics has acquired 2 companies including Novellus and IRX Therapeutics. Brooklyn ImmunoTherapeutics has not made any investments as of now.

Here is the latest report on Brooklyn ImmunoTherapeutics's sector: